P/E at 35.2 vs Industry's 36.44: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Discount in a High-P/E Sector

The pharmaceutical and biotechnology sector currently trades at an average P/E of 36.44, reflecting elevated valuations driven by growth expectations and innovation pipelines. Against this backdrop, Sun Pharmaceutical Industries Ltd’s P/E of 35.2 represents a modest discount of approximately 3.4%. This suggests that the market is pricing in slightly more conservative earnings growth or risk factors relative to its peers. The company’s large-cap status, with a market capitalisation of ₹4,44,717 crore, supports its premium valuation compared to smaller sector constituents, but the discount relative to the industry average invites questions about the sustainability of its earnings trajectory — previously rated Buy, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Divergent Momentum

Examining returns over multiple periods reveals a nuanced performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a 14.57% gain, significantly outperforming the Sensex’s 10.03% loss. This outperformance extends to longer horizons, with three-year and five-year returns of 61.44% and 140.99% respectively, dwarfing the Sensex’s 9.68% and 26.07% gains over the same periods. However, the short-term picture is less robust. The stock’s one-month return is down 1.39%, though still outperforming the Sensex’s 4.28% decline, and the three-month return of 1.99% contrasts with the Sensex’s 3.57% fall. This suggests a recent moderation in momentum, possibly reflecting sector headwinds or company-specific developments — is this a temporary pause or a sign of deeper challenges?

Moving Average Configuration: Mixed Technical Signals

The technical setup for Sun Pharmaceutical Industries Ltd is characterised by a complex moving average configuration. The stock currently trades above its 200-day moving average, a long-term bullish indicator, but remains below its 5-day, 20-day, 50-day, and 100-day moving averages. This pattern often signals a recent recovery attempt within a broader downtrend or consolidation phase. The stock has gained for two consecutive days, rising 1.24%, and outperformed the sector by 0.44% today, but the inability to surpass shorter-term averages suggests resistance remains. The 200-day average support may provide a floor, but the near-term trend requires confirmation — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Context: Mixed Results Amidst Pharmaceutical Volatility

The Pharmaceuticals & Biotechnology sector has seen 28 stocks declare results recently, with 13 reporting positive outcomes, 11 flat, and 4 negative. This distribution indicates a broadly stable sector environment with pockets of strength and weakness. Sun Pharmaceutical Industries Ltd’s performance aligns with this mixed sector backdrop, outperforming the Sensex and many peers over the medium to long term, but showing signs of short-term volatility. The sector’s average P/E of 36.44 reflects investor optimism, yet the presence of flat and negative results among peers may be tempering enthusiasm — how will this sector mix influence Sun Pharmaceutical Industries Ltd’s outlook?

Rating Context: Previously Rated Buy, Now Reassessed

On 3 September 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from Buy to Hold, reflecting a reassessment of its valuation and performance metrics. The current Mojo Score stands at 67.0, indicating a moderate confidence level in the stock’s prospects relative to its peers. This change suggests a more cautious stance given the recent performance moderation and technical signals. The P/E discount to the sector average, combined with the mixed moving average configuration, supports this tempered view — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced Valuation and Mixed Momentum

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight valuation discount to its sector, with strong long-term returns but recent momentum that is less convincing. The moving average configuration highlights a stock in a tentative recovery phase, supported by the 200-day moving average but challenged by shorter-term resistance levels. Sector results are mixed, reflecting broader industry volatility. The rating update from Buy to Hold underscores a more cautious stance, balancing the company’s historical outperformance against recent technical and performance signals — what does the current rating mean for investors in Sun Pharmaceutical Industries Ltd?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today